Patient Brochure

 Spravato is used to treat adults with:

• Treatment-resistant depression (TRD): depression that hasn't responded to at least two different antidepressants.
• Major depressive disorder (MDD) with acute suicidal ideation or behavior, in conjunction with oral antidepressants.

It is a nasal spray medication, administered in a certified medical office under direct supervision. Patients are monitored for at least 2 hours afterward due to potential side effects like sedation or dissociation. 

Weeks 1–4: Twice per week.

Weeks 5–8: Once per week.

Week 9 and beyond: Usually every 1–2 weeks, depending on individual response.

  Each visit typically lasts 2 hours:

• Administration: a few minutes
• Monitoring: at least 2 hours
• Patients need someone to drive them home.

  While esketamine has potential for abuse, Spravato is administered under strict medical supervision in certified clinics to minimize risk. The FDA mandates a REMS (Risk Evaluation and Mitigation Strategy) program for this reason. 

  Spravato contains esketamine, a derivative of ketamine, but it is FDA-approved and specifically formulated for nasal administration under medical supervision. 

  Some patients experience relief in hours to days, especially when used for suicidal ideation. However, response times vary, and ongoing treatment is usually necessary. 

 Many insurance plans do cover Spravato, but prior authorization is often required. This is a service provided on behalf of the site's administration staff. Coverage and out-of-pocket costs can vary. For commercial plans, Spravato offers a savings card up to $8500. per year to help cover the costs of deductibles and co-insurance. This can sometimes help patients reach their yearly deductibles faster with less out-of-pocket costs to them.